88 related articles for article (PubMed ID: 7517020)
1. FK 506 for vascular permeability factor production in minimal change nephrotic syndrome.
Maruyama K; Tomizawa S; Seki Y; Arai H; Ogawa T; Kuroume T
Nephron; 1994; 66(4):486-7. PubMed ID: 7517020
[No Abstract] [Full Text] [Related]
2. Inhibition of vascular permeability factor production by ciclosporin in minimal change nephrotic syndrome.
Maruyama K; Tomizawa S; Seki Y; Arai H; Kuroume T
Nephron; 1992; 62(1):27-30. PubMed ID: 1436287
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-18 and interleukin-12 synergize to stimulate the production of vascular permeability factor by T lymphocytes in normal subjects and in patients with minimal-change nephrotic syndrome.
Matsumoto K; Kanmatsuse K
Nephron; 2000 Jun; 85(2):127-33. PubMed ID: 10867518
[TBL] [Abstract][Full Text] [Related]
4. Studies of vascular permeability factor derived from T lymphocytes and inhibitory effect of plasma on its production in minimal change nephrotic syndrome.
Tomizawa S; Maruyama K; Nagasawa N; Suzuki S; Kuroume T
Nephron; 1985; 41(2):157-60. PubMed ID: 3876517
[TBL] [Abstract][Full Text] [Related]
5. Transforming growth factor-beta1 inhibits vascular permeability factor release by T cells in normal subjects and in patients with minimal-change nephrotic syndrome.
Matsumoto K; Kanmatsuse K
Nephron; 2001 Feb; 87(2):111-7. PubMed ID: 11244304
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-15 and interleukin-12 have an additive effect on the release of vascular permeability factor by peripheral blood mononuclear cells in normals and in patients with nephrotic syndrome.
Matsumoto K; Kanmatsuse K
Clin Nephrol; 1999 Jul; 52(1):10-8. PubMed ID: 10442490
[TBL] [Abstract][Full Text] [Related]
7. Effect of supernatants derived from T lymphocyte culture in minimal change nephrotic syndrome on rat kidney capillaries.
Maruyama K; Tomizawa S; Shimabukuro N; Fukuda T; Johshita T; Kuroume T
Nephron; 1989; 51(1):73-6. PubMed ID: 2783765
[TBL] [Abstract][Full Text] [Related]
8. Increased IL-12 release by monocytes in nephrotic patients.
Matsumoto K; Kanmatsuse K
Clin Exp Immunol; 1999 Aug; 117(2):361-7. PubMed ID: 10444271
[TBL] [Abstract][Full Text] [Related]
9. Elevated vascular endothelial growth factor levels in the urine of patients with minimal-change nephrotic syndrome.
Matsumoto K; Kanmatsuse K
Clin Nephrol; 2001 Apr; 55(4):269-74. PubMed ID: 11334311
[TBL] [Abstract][Full Text] [Related]
10. Interleukin 10 inhibits vascular permeability factor release by peripheral blood mononuclear cells in patients with lipoid nephrosis.
Matsumoto K
Nephron; 1997; 75(2):154-9. PubMed ID: 9041534
[TBL] [Abstract][Full Text] [Related]
11. Release of the vascular permeability factor in minimal change nephrotic syndrome is related to CD4+ lymphocytes.
Tomizawa S; Nagasawa N; Maruyama K; Shimabukuro N; Arai H; Kuroume T
Nephron; 1990; 56(3):341-2. PubMed ID: 1981805
[No Abstract] [Full Text] [Related]
12. Interleukin 10 and interleukin 13 synergize to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with lipoid nephrosis.
Matsumoto K; Ohi H; Kanmatsuse K
Nephron; 1997; 77(2):212-8. PubMed ID: 9346389
[TBL] [Abstract][Full Text] [Related]
13. Vascular permeability increasing factor (VPF) in IgA nephropathy.
Bakker WW; Beukhof JR; van Luijk WH; van der Hem GK
Clin Nephrol; 1982 Oct; 18(4):165-7. PubMed ID: 7140031
[TBL] [Abstract][Full Text] [Related]
14. Interleukin 12 upregulates the release of vascular permeability factor by peripheral blood mononuclear cells from patients with lipoid nephrosis.
Matsumoto K; Ohi H; Kanmatsuse K
Nephron; 1998; 78(4):403-9. PubMed ID: 9578066
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-4 cooperates with interleukin-10 to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with minimal-change nephrotic syndrome.
Matsumoto K; Ohi H; Kanmatsuse K
Am J Nephrol; 1999; 19(1):21-7. PubMed ID: 10085445
[TBL] [Abstract][Full Text] [Related]
16. Studies of glomerular permeability factor (GPF) in focal segmental glomerular sclerosis and the relationship between GPF and vascular permeability factor (VPF).
Kondo S; Yoshizawa N; Kusumi Y; Takeuchi A; Torikata C
Clin Nephrol; 1999 Nov; 52(5):278-84. PubMed ID: 10584990
[TBL] [Abstract][Full Text] [Related]
17. Commentary on prostatic neovascularization and vascular endothelial growth factor.
Chevalier S
J Urol; 1997 Jun; 157(6):2040-1. PubMed ID: 9146575
[No Abstract] [Full Text] [Related]
18. Cyclosporine inhibition of vascular endothelial growth factor production in rheumatoid synovial fibroblasts.
Cho ML; Cho CS; Min SY; Kim SH; Lee SS; Kim WU; Min DJ; Min JK; Youn J; Hwang SY; Park SH; Kim HY
Arthritis Rheum; 2002 May; 46(5):1202-9. PubMed ID: 12115224
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with sirolimus (rapamycin) and tacrolimus (FK-506) in treatment of refractory minimal change nephropathy, a clinical case report.
Patel P; Pal S; Ashley C; Sweny P; Burns A
Nephrol Dial Transplant; 2005 May; 20(5):985-7. PubMed ID: 15741203
[No Abstract] [Full Text] [Related]
20. Downregulation of vascular endothelial growth factor and its receptors in the kidney in rats with puromycin aminonucleoside nephrosis.
Fan L; Wakayama T; Yokoyama S; Amano O; Iseki S
Nephron; 2002 Jan; 90(1):95-102. PubMed ID: 11744811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
